Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > 3 (or more) treatments

<< Previous

Bullboard Posts

Next >>

Post by Gman620on May 13, 2023 9:59am

298 Views

Post# 35446817

3 (or more) treatments

Would a third treatment add significant testing burden (and cost) to the trial? I assume it would be done only for those that went from CR to NR, but it could be more broad. It seems logical that this could improve outcomes, but safety profile and protocols would need to be updated/written.

<< Previous

Bullboard Posts

Next >>

Two micro-cap stocks with strong fundamentals